These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10834383)

  • 1. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.
    Grobholz R; Bohrer MH; Siegsmund M; Jünemann KP; Bleyl U; Woenckhaus M
    Pathol Res Pract; 2000; 196(5):277-84. PubMed ID: 10834383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas].
    Bohrer MH; Schmoll J
    Verh Dtsch Ges Pathol; 1993; 77():107-10. PubMed ID: 7511265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker".
    Abrahamsson PA; Falkmer S; Fält K; Grimelius L
    Pathol Res Pract; 1989 Sep; 185(3):373-80. PubMed ID: 2813190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade.
    Gyftopoulos K; Vourda K; Sakellaropoulos G; Perimenis P; Athanasopoulos A; Papadaki E
    Urol Int; 2011; 87(4):464-9. PubMed ID: 21912077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME; Deeble PD; Lakhani S; Parsons SJ
    Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
    Abrahamsson PA; Cockett AT; di Sant'Agnese PA
    Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
    Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
    Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma].
    Li GZ; Zeng L; Zhang J; Yuan YM; Yang XY; Wang JH; Na YQ; Guo YL
    Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):493-5. PubMed ID: 14575578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergent neuroendocrine differentiation in prostatic carcinoma.
    di Sant' Agnese PA
    Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance.
    Hong SM; Kim MJ; Pi DY; Jo D; Yu E; Ro JY
    Hum Pathol; 2005 Jul; 36(7):732-40. PubMed ID: 16084941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
    Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
    Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate.
    Van de Voorde WM; Van Poppel HP; Verbeken EK; Oyen RH; Baert LV; Lauweryns JM
    Mod Pathol; 1995 Aug; 8(6):591-8. PubMed ID: 8532689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
    Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
    J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.